Press releases
2023
Curasight to present at Redeye Fight Cancer Seminar
January 16, 2023
| Regulatory
Copenhagen, Denmark, 16 January 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at Redeye Fight Cancer Seminar Outlook - January 19, 2023.
2022
Interim Report January – September 2022
November 24, 2022
| Regulatory
Copenhagen, Denmark, 24 November 2022 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight to present at HC Andersen Capital
November 23, 2022
| Regulatory
Copenhagen, Denmark, 23 November 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q3 2022 at HC Andersen Capital, 28 November 2022.
Curasight to present at SEB Healthcare Seminar 2022
November 17, 2022
| Regulatory
Copenhagen, Denmark, 17 November 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at SEB Healthcare Seminar 2022, 21 November 2022.
Curasight initiates pre-clinical studies with uTREAT[®] therapy in head and neck cancer (HNSCC) and neuroendocrine tumors (NET)
October 13, 2022
| Regulatory
Copenhagen, Denmark, 13 October 2022 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announces that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT[®]) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.
Transaction with shares in Curasight A/S made by managerial employee
September 4, 2022
| Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS).
The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.
The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.
Curasight to present at HC Andersen Capital
August 25, 2022
| Regulatory
Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q2 2022 at HC Andersen Capital, 29 August 2022.
Interim Report January – June 2022
August 25, 2022
| Regulatory
Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Recruitment completed in uPAR-PET study in brain cancer
June 30, 2022
| Regulatory
Copenhagen, Denmark, 30 June 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has now completed the inclusion of patients
Transaction with shares in Curasight A/S made by managerial employee
June 24, 2022
| Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS).
The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted in the period 9 – 10 June 2022.
The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted in the period 9 – 10 June 2022.